| Inflammatory marker | | | | | | Study | Formulation | Before | After | ES∗∗ | p∗∗∗ |
| CRP (mg/l) | | | | | | Morin-Papunen et al, 2003 | EE 35 μg/ CPA 2 mg | 2.91 | 4.58 | +1.67 | <0.001 | Chen et al, 2010 | EE 35 μg/ CPA 2 mg | 0.7 | 1.2 | +0.5 | 0.002 | Teede et al, 2010 | EE 35 μg/ CPA 2 mg | 3.5 | 4.7 | +1.2 | 0.001 | Ibanez et al, 2011 | EE 35 μg/ CPA 2 mg | 0.9 | 1.7 | +0.8 | <0.05 | Gode et al, 2011 | EE 35 μg/ CPA 2 mg | 3.31 | 3.87 | +0.56 | >0.05 | Diaz et al, 2012 | EE 35 μg/ CPA 2 mg | 0.9 | 2.6 | +1.7 | <0.05 | Ibanez et al, 2013 | EE 35 μg/ CPA 2 mg | 0.9 | 3.2 | +2.3 | <0.01 | Christakou et al, 2014 | EE 35 μg/ CPA 2 mg | 1.36 | 2.63 | +1.27 | <0.001 | Kahraman et al, 2014 | EE 35 μg/ CPA 2 mg | 1.21 | 3.31 | +2.1 | <0.05 | Dardzinska et al, 214 | EE 35 μg/ CPA 2 mg | 0.77 | 1.70 | +0.93 | <0.001 | Orio et al, 2016 | EE 35 μg/ CPA 2 mg | 1.80 | 1.90 | +0.1 | >0.05 | Tfayli et al, 2011 | EE 30 μg/ DRSP 3 mg | 1.7 | 3.8 | +2.1 | <0.001 | Harmanci et al, 2013 | EE 30 μg/ DRSP 3 mg | 0.50 | 1.5 | +1 | <0.05 | Kahraman et al, 2014 | EE 30 μg/ DRSP 3 mg | 0.93 | 1.22 | +0.29 | 0.040 | Christakou et al, 2014 | EE 30 μg/ DRSP 3 mg | 1.09 | 1.93 | +0.84 | <0.001 | Yildzhan et al, 2015 | EE 30 μg/ DRSP 3 mg | 3.77 | 4.32 | +0.55 | 0.005 | Orio et al, 2016 | EE 30 μg/ DRSP 3 mg | 1.8 | 1.9 | +0.1 | <0.05 | Vieira et al, 2012 | EE 30 μg/ CMA 2 mg | 2.1 | 6.0 | +3.9 | <0.05 | Yildzhan et al, 2015 | EE 30 μg/ CMA 2 mg | 4.26 | 0.72 | -3.54 | 0.004 | Hoeger et al, 2008 | EE 30 μg/ DSG 0.15 mg | 6.8 | 9.5 | +2.7 | <0.05 | Kilic et al, 2011 | EE 30 μg/ DSG 0.15 mg | 1.67 | 3.23 | +1.56 | <0.001 | Banaszewska et al, 2007 | EE 20 μg/ DSG 0.15 mg | 1.61 | 1.70 | +0.09 | 0.74 | Essah et al, 2011 | EE 30 μg/ DSG 0.15-0.25 mg | 4.9 | 5.6 | +0.7 | 0.280 |
|
|